Ticker

Knight Therapeutics Inc. (GUD:CA) Q4 2025 Earnings Call Transcript

Delivered record-high revenues, Adjusted EBITDA 1 , Adjusted EBITDA per shar e 1 since inception Generated record high cash flow from operations since inception Provides 2026 revenues guidance of $490 million to $510 million and adjusted EBITDA 1 of approximately 15%

MONTREAL, March 12, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and year end 2025 financial results on Thursday, March 19, 2026 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this…

Knight Therapeutics (OTCMKTS:KHTRF - Get Free Report) is anticipated to release its resultson Thursday, March 19th. Analysts expect Knight Therapeutics to post earnings of ($0.0029) per share and revenue of $118.1870 million for the quarter. Knight Therapeutics Stock Performance Shares of KHTRF opened at $4.32 on Thursday. Knight Therapeutics has a 12 month low of

MONTREAL, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a marketing authorization application to ANVISA, the Brazilian health regulatory agency, for NIKTIMVO® (axatilimab) for the treatment of chronic graft-versus-host disease (GVHD) after…